#United States #Hematology #Boulder #Foresight Diagnostics #CLARITY MRD

Foresight Diagnostics Set to Present Key Data on CLARITY™ MRD Assay

Foresight Diagnostics, a pioneer in ultra-sensitive minimal residual disease (MRD) detection technologies, has exciting developments on the horizon. The company has announced the independent validation data for its CLARITY™ MRD assay, which will be presented at two prestigious upcoming international conferences: the 2025 European Hematology Association (EHA) Congress in Milan, Italy and the International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland.

The presentations are scheduled for June 12 and 19, 2025, respectively, where researchers will discuss findings from a multi-center study conducted in collaboration with several reputable institutions, including the Amsterdam University Medical Centers and the Netherlands Comprehensive Cancer Organization (IKNL). This comprehensive study is significant as it has gathered real-world data from more than 50 medical centers across the Netherlands and Belgium, focusing on patients diagnosed with diffuse large B-cell lymphoma (DLBCL).

Dr. David Kurtz, the Chief Medical Officer at Foresight Diagnostics, expressed optimism about showcasing their findings, stating, "We are grateful to present our data at major medical meetings this spring, validating our science and the real-world utility of ultra-sensitive ctDNA-MRD technology." As the clinical market launch approaches in 2026, Foresight is preparing to integrate the CLARITY™ MRD assay into routine clinical practices, with confidence bolstered by its recent inclusion in clinical guidelines for B-cell lymphoma.

The presentations at both conferences will highlight not only the effectiveness of the CLARITY™ MRD assay but also its impact on patient management and treatment stratification. Drs. Steven Wang and Martine Chamuleau, who are leading the study, pointed out that the ultra-sensitive ctDNA-MRD detection provides substantial prognostic insight that goes beyond traditional imaging techniques and clinical evaluations. They believe this innovative assay could fundamentally change how patients are stratified based on risks and how they are managed post-treatment.

Presentation Details

• - EHA Congress: Title: Validation of end of treatment ctDNA-MRD by PhasED-Seq in DLBCL patients from a national trial.

Presenter: Dr. Martine Chamuleau
Session: Aggressive Non-Hodgkin Lymphoma
Date/Time: June 12, 2025, 5:00 PM - 5:15 PM CEST

• - ICML Conference: Title: Validation of end of treatment ctDNA-MRD by PhasED-Seq in DLBCL patients from a national HOVON trial.

Presenter: Dr. Martine Chamuleau
Session: Liquid biopsy for response assessment
Date/Time: June 19, 2025, 2:15 PM - 2:30 PM CEST

Foresight Diagnostics will also be represented in various other presentations at both conferences, discussing the prognostic values of their ctDNA assays and the innovations in treatment technologies.

About Foresight Diagnostics

Established as a privately held entity, Foresight Diagnostics specializes in cancer diagnostics and maintains a CLIA-registered laboratory. The firm’s landmark liquid biopsy platform—Foresight CLARITY™—is recognized for its remarkable sensitivity in measuring minimal residual disease. With a detection limit reportedly in parts per million, the CLARITY™ assay aims to refine treatment approaches for patients suffering from solid tumor and hematologic malignancies, bridging the gap between innovative technology and actionable clinical insights. For more information on their work and advancements, visit their website at foresight-dx.com and follow them on social media.